指南与共识重症综合管理与镇静镇痛

成人ECMO药理学研究议程:德尔菲法立场文件

Pharmacological Research Agenda on Adult Extracorporeal Membrane Oxygenation Using the Delphi Method: A Position Paper of the Extracorporeal Membrane Oxygenation Pharmacology Network.
指南 / 共识 · Crit Care Med · 2025-07-30
一句话结论ECMO药理学网络通过德尔菲法确定六项成人ECMO药理学关键研究优先领域,指出现有文献存在重大知识缺口。

该立场文件由ECMO药理学网络25名来自13个国家的专家参与,采用结构化德尔菲共识流程确定成人ECMO药理学关键研究优先领域。最终确定六项优先领域:药代动力学/药效学报告、ECMO与肾脏替代治疗的相互作用、抗菌药物剂量、疼痛与躁动的镇痛镇静、呼吸做功增加时的镇静与神经肌肉阻滞剂、抗凝治疗。针对每项优先领域进行文献综述,强调现有文献存在重大缺口,需全面研究以改善ECMO患者药物治疗和临床结局,并为制定循证指南提供依据。

要点

  • 德尔菲共识确定六项成人ECMO药理学研究优先领域:药代动力学/药效学报告、ECMO与肾脏替代治疗相互作用、抗菌药物剂量、镇痛镇静、呼吸做功增加时的镇静与神经肌肉阻滞剂、抗凝治疗。
  • ECMO回路和基础危重病可改变药物药代动力学和药效学,导致ECMO支持患者药物治疗面临独特挑战。
  • 针对六项优先领域的文献综述强调现有证据存在重大缺口,需全面研究以改善ECMO患者药物治疗和临床结局。
  • 该立场文件由25名来自13个国家的ECMO药理学专家参与,通过迭代匿名投票确定研究优先领域。

适用人群与场景

  • 成人严重心脏或呼吸衰竭接受ECMO支持的患者。

研究设计与关键结果

  • 该立场文件由ECMO药理学网络25名来自13个国家的专家参与,采用结构化德尔菲共识流程确定研究优先领域。
  • 通过迭代匿名投票确定六项关键ECMO药物治疗研究优先领域:1)药代动力学/药效学报告;2)ECMO与肾脏替代治疗的相互作用;3)抗菌药物剂量;4)疼痛与躁动的镇痛镇静;5)呼吸做功增加时的镇静与神经肌肉阻滞剂;6)抗凝治疗。
  • 针对每项优先领域进行文献综述,强调现有文献存在重大缺口,需全面研究以改善ECMO患者药物治疗、临床结局并促进循证指南制定。

证据类型、等级与局限

  • 证据类型:国际专家小组立场文件,采用德尔菲共识流程。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

指南或共识出处

  • ECMO药理学网络(Extracorporeal Membrane Oxygenation Pharmacology Network)立场文件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) is a critical intervention for patients with severe cardiac or respiratory failure. However, pharmacological management for ECMO-supported patients presents unique challenges due to alterations in drug pharmacokinetics and pharmacodynamics induced by the ECMO circuit and underlying critical illness. This position paper identifies key research priorities in ECMO pharmacology using a structured Delphi consensus process and provides a focused review of current evidence and knowledge gaps to inform future research and clinical practice.

DATA SOURCES: An international panel of 25 ECMO pharmacology experts from 13 countries representing the ECMO Pharmacology Network contributed to this position paper. Literature was reviewed to summarize current evidence and identify knowledge gaps in ECMO pharmacology.

STUDY SELECTION: The Delphi process involved iterative, anonymous voting by the expert panel to propose key research priorities. Items selected were based on their perceived importance to improving clinical outcomes and advancing pharmacological management in ECMO-supported patients.

DATA EXTRACTION: Key research priorities were identified, and a detailed literature review was conducted for each, focusing on pharmacokinetics/pharmacodynamics, related therapeutic challenges, and knowledge gaps. Future research directions were outlined.

DATA SYNTHESIS: Six critical ECMO pharmacotherapy research priorities were identified: 1) pharmacokinetics/pharmacodynamics reporting, 2) interactions between ECMO and renal replacement therapy, 3) antimicrobial dosing, 4) analgesia and sedation for pain and agitation, 5) sedation and neuromuscular blocking agents for increased work of breathing, and 6) anticoagulation. The review for the key research priorities highlighted substantial gaps in the existing literature, emphasizing the need for comprehensive studies addressing these issues to enhance pharmacotherapy in ECMO patients, improve clinical outcomes, and contribute to the development of evidence-based guidelines for this complex population.

CONCLUSIONS: ECMO presents unique challenges to drug pharmacokinetics and pharmacodynamics, complicating pharmacotherapy in critically ill patients. Further research addressing identified gaps is essential to develop evidence-based treatment strategies and enhance patient outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Morales Castro D, Al-Fares AA, Paternoster G, et al. Pharmacological Research Agenda on Adult Extracorporeal Membrane Oxygenation Using the Delphi Method: A Position Paper of the Extracorporeal Membrane Oxygenation Pharmacology Network. Crit Care Med. 2025. PMID: 40736325. doi:10.1097/CCM.0000000000006806

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。